title: [Therapy of brain metastasis based on the RPA classification].
abstract: RPA classification of patients suffering from brain metastases is not widely used in Hungary. The authors reviewed the RPA disposition-based therapeutic recommendations in the literature. Retrospective analysis of their 123 brain metastatic cases showed 3.8 months median, 34.1% 1-year and 7.9% 2-year overall survival. Patient number and median survival in subgroups: RPA 1: 42/14 months, RPA 2: 38/6,2 months, RPA 3a: 6/3.1 months, 3b: 13/2 months, 3c: 10/0.7 months. Median survival of patients with brain metastases from cancer of unknown primary (CUP) was 3 months. In RPA class 1 and 2, 10% undertreatment has been found for solid brain metastases, and all of the 3c patients were over-treated according to literature recommendations. The authors strongly recommend the use of RPA classification in the management of brain metastases and in contemplation of the capacity of radiotherapy/neurosurgery and oncology.
authors.affiliation: Sugárterápia Tanszék, Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Debrecen 4012, Hungary. horvakos@freemail.hu
authors.forename: Akos
authors.initials: A
authors.lastname: Horváth
authors.forename: Alicia
authors.initials: A
authors.lastname: Gáspár
authors.forename: András
authors.initials: A
authors.lastname: Bajcsay
authors.forename: Kornélia
authors.initials: K
authors.lastname: Szluha
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Adamecz
authors.forename: László
authors.initials: L
authors.lastname: Lengyel
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D001932:Brain Neoplasms / Q000556:secondary* / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009382:Neoplasms, Unknown Primary / Q000473:pathology*; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome